• Je něco špatně v tomto záznamu ?

Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]

JC. Fernandez-Checa, P. Bagnaninchi, H. Ye, P. Sancho-Bru, JM. Falcon-Perez, F. Royo, C. Garcia-Ruiz, O. Konu, J. Miranda, O. Lunov, A. Dejneka, A. Elfick, A. McDonald, GJ. Sullivan, GP. Aithal, MI. Lucena, RJ. Andrade, B. Fromenty, M....

. 2021 ; 75 (4) : 935-959. [pub] 20210624

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012152

Grantová podpora
MR/K017047/1 Medical Research Council - United Kingdom
MR/R015635/1 Medical Research Council - United Kingdom
BB/L023687/1 Biotechnology and Biological Sciences Research Council - United Kingdom
P50 AA011999 NIAAA NIH HHS - United States

Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.

Cell Death and Proliferation Institute of Biomedical Research of Barcelona Spain

Center for Regenerative Medicine Institute for Regenerative and Repair The University of Edinburgh Edinburgh UK EH16 4UU

Center for Toxicogenomics and Human Health Genetics Oncology and Human Toxicology NOVA Medical School Faculty of Medical Sciences Universidade NOVA de Lisboa Lisbon Portugal

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Instituto de Salud Carlos 3 Madrid 28029 Spain

Department of Immunology Ophthalmology and ENT Complutense University School of Medicine 28040 Madrid Spain

Department of Molecular Biology and Genetics Faculty of Science Bilkent University Ankara Turkey

Department of Optical and Biophysical Systems Institute of Physics of the Czech Academy of Sciences Prague Czech Republic

Department of Pediatric Research Oslo University Hosptial Oslo Norway

Exosomes Laboratory Center for Cooperative Research in Biosciences Derio Bizkaia 48160 Spain

Health Research Institute Gregorio Marañón 28007 Madrid Spain

Hybrid Technology Hub Center of Excellence Institute of Basic Medical Sciences University of Oslo Oslo Norway

IKERBASQUE Basque Foundation for Science Bilbao Bizkaia 48015 Spain

INSERM Univ Rennes INRAE Institut NUMECAN UMR_A 1341 UMR_S 1241 F 35000 Rennes France

Institute for Bioengineering School of Engineering The University of Edinburgh Edinburgh EH8 3DW UK

Institute of Biological Chemistry Biophysics and Bioengineering Heriot Watt University Edinburgh EH12 2AS Scotland UK

Instituto Investigaciones Biomédicas August Pi i Sunyer Universitat de Barcelona Spain

Interdisciplinary Neuroscience Program Bilkent University Ankara Turkey

Liver Unit Hospital Clínic Barcelona Spain

National Institute for Health Research Nottingham Biomedical Research Centre Nottingham University Hospital NHS Trust and University of Nottingham Nottingham UK

Research Institute for iMedicines Faculty of Pharmacy Universidade de Lisboa 1649 003 Lisbon Portugal

School of Engineering Institute for Bioengineering The University of Edinburgh Faraday Building Colin Maclaurin Road EH9 3 DW Scotland UK

Servicio de Farmacología Clínica Instituto de Investigación Biomédica de Málaga IBIMA Hospital Universitario Virgen de la Victoria UICEC SCReN Universidad de Málaga Málaga Spain

UNAM Institute of Materials Science and Nanotechnology Bilkent University Ankara Turkey

Unidad de Gestión Clínica de Enfermedades Digestivas Instituto de Investigación Biomédica de Málaga IBIMA Hospital Universitario Virgen de la Victoria Universidad de Málaga Malaga Spain

University of Oslo and the Oslo University Hospital Oslo Norway

USC Research Center for ALPD Keck School of Medicine Los Angeles United States CA 90033

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012152
003      
CZ-PrNML
005      
20220506130533.0
007      
ta
008      
220425s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jhep.2021.06.021 $2 doi
035    __
$a (PubMed)34171436
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Fernandez-Checa, Jose C $u Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), Consejo Superior Investigaciones Científicas (CSIC), Spain; Liver Unit, Hospital Clínic, Barcelona, Spain; Instituto Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; USC Research Center for ALPD, Keck School of Medicine, Los Angeles, United States, CA 90033. Electronic address: checa229@yahoo.com
245    10
$a Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET] / $c JC. Fernandez-Checa, P. Bagnaninchi, H. Ye, P. Sancho-Bru, JM. Falcon-Perez, F. Royo, C. Garcia-Ruiz, O. Konu, J. Miranda, O. Lunov, A. Dejneka, A. Elfick, A. McDonald, GJ. Sullivan, GP. Aithal, MI. Lucena, RJ. Andrade, B. Fromenty, M. Kranendonk, FJ. Cubero, LJ. Nelson
520    9_
$a Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.
650    _2
$a paracetamol $x škodlivé účinky $7 D000082
650    _2
$a lékové postižení jater $x etiologie $x patofyziologie $7 D056486
650    12
$a konsensus $7 D032921
650    _2
$a lidé $7 D006801
650    _2
$a játra $x účinky léků $7 D008099
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bagnaninchi, Pierre $u Center for Regenerative Medicine, Institute for Regenerative and Repair, The University of Edinburgh, Edinburgh, UK, EH16 4UU; School of Engineering, Institute for Bioengineering, The University of Edinburgh, Faraday Building, Colin Maclaurin Road, EH9 3 DW, Scotland, UK
700    1_
$a Ye, Hui $u Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine, 28040 Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), 28007 Madrid, Spain
700    1_
$a Sancho-Bru, Pau $u Instituto Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain
700    1_
$a Falcon-Perez, Juan M $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, 48160, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Bizkaia, 48015, Spain
700    1_
$a Royo, Felix $u Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, 48160, Spain
700    1_
$a Garcia-Ruiz, Carmen $u Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), Consejo Superior Investigaciones Científicas (CSIC), Spain; Liver Unit, Hospital Clínic, Barcelona, Spain; Instituto Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; USC Research Center for ALPD, Keck School of Medicine, Los Angeles, United States, CA 90033
700    1_
$a Konu, Ozlen $u Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey; Interdisciplinary Neuroscience Program, Bilkent University, Ankara, Turkey; UNAM-Institute of Materials Science and Nanotechnology, Bilkent University, Ankara, Turkey
700    1_
$a Miranda, Joana $u Research Institute for iMedicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal
700    1_
$a Lunov, Oleg $u Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Dejneka, Alexandr $u Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Elfick, Alistair $u Institute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh EH8 3DW, UK
700    1_
$a McDonald, Alison $u Institute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh EH8 3DW, UK
700    1_
$a Sullivan, Gareth J $u University of Oslo and the Oslo University Hospital, Oslo, Norway; Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Pediatric Research, Oslo University Hosptial, Oslo, Norway
700    1_
$a Aithal, Guruprasad P $u National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospital NHS Trust and University of Nottingham, Nottingham, UK
700    1_
$a Lucena, M Isabel $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, UICEC SCReN, Universidad de Málaga, Málaga, Spain
700    1_
$a Andrade, Raul J $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Unidad de Gestión Clínica de Enfermedades Digestivas, Instituto de Investigación, Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain
700    1_
$a Fromenty, Bernard $u INSERM, Univ Rennes, INRAE, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France
700    1_
$a Kranendonk, Michel $u Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
700    1_
$a Cubero, Francisco Javier $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine, 28040 Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), 28007 Madrid, Spain
700    1_
$a Nelson, Leonard J $u Center for Regenerative Medicine, Institute for Regenerative and Repair, The University of Edinburgh, Edinburgh, UK, EH16 4UU; School of Engineering, Institute for Bioengineering, The University of Edinburgh, Faraday Building, Colin Maclaurin Road, EH9 3 DW, Scotland, UK; Institute of Biological Chemistry, Biophysics and Bioengineering (IB3), School of Engineering and Physical Sciences (EPS), Heriot-Watt University, Edinburgh EH12 2AS, Scotland, UK. Electronic address: l.nelson@ed.ac.uk
773    0_
$w MED00010017 $t Journal of hepatology $x 1600-0641 $g Roč. 75, č. 4 (2021), s. 935-959
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34171436 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130525 $b ABA008
999    __
$a ok $b bmc $g 1789655 $s 1163353
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 75 $c 4 $d 935-959 $e 20210624 $i 1600-0641 $m Journal of hepatology $n J Hepatol $x MED00010017
GRA    __
$a MR/K017047/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a MR/R015635/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a BB/L023687/1 $p Biotechnology and Biological Sciences Research Council $2 United Kingdom
GRA    __
$a P50 AA011999 $p NIAAA NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...